Health Care·Biotechnology·$29.2B
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-1.39 | N/A | -396.43% |
| Revenue | N/A | N/A | N/A |
management commentary, guidance changes, and full analysis available with Pro.
| EPS | $-1.39 | N/A | -396.43% |
| Revenue | N/A | N/A | N/A |
Tone: Defensive
Management acknowledged the difficulties faced during the quarter. They emphasized a commitment to improving performance but did not offer specific future expectations.
Management did not provide specific guidance for future quarters.
The company is focused on addressing operational challenges.
Insmed Inc reported a significant loss per share, which contributed to a 2.11% decline in stock price following the earnings announcement. The lack of revenue information and guidance may raise concerns among investors about the company's future performance. Management's defensive tone suggests they are aware of the challenges ahead but are focused on addressing them.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
SYSCO CORP
Nov 7, 2011